Brokerages Set Nkarta, Inc. (NASDAQ:NKTX) Target Price at $13.50

Nkarta, Inc. (NASDAQ:NKTX) has received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $13.50.

Several analysts have issued reports on NKTX shares. Wall Street Zen cut Nkarta from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Nkarta in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 price objective on shares of Nkarta in a research report on Wednesday, August 13th. Finally, Stifel Nicolaus lowered their price objective on Nkarta from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 14th.

Institutional Trading of Nkarta

Institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Nkarta in the 1st quarter worth $32,000. Savant Capital LLC acquired a new stake in Nkarta during the 2nd quarter worth about $36,000. CWM LLC lifted its position in Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company’s stock worth $52,000 after acquiring an additional 27,361 shares during the period. Cerity Partners LLC acquired a new stake in Nkarta during the 1st quarter worth about $55,000. Finally, Deutsche Bank AG lifted its position in Nkarta by 36.3% during the 1st quarter. Deutsche Bank AG now owns 58,812 shares of the company’s stock worth $108,000 after acquiring an additional 15,655 shares during the period. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Trading Down 7.6%

Shares of NASDAQ NKTX opened at $2.30 on Monday. The stock has a market capitalization of $163.37 million, a PE ratio of -1.55 and a beta of 0.86. The stock’s fifty day simple moving average is $2.16 and its two-hundred day simple moving average is $1.96. Nkarta has a 12-month low of $1.31 and a 12-month high of $4.55.

Nkarta (NASDAQ:NKTX) last announced its earnings results on Tuesday, August 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.06. On average, equities analysts predict that Nkarta will post -1.7 earnings per share for the current fiscal year.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.